» Articles » PMID: 11502536

Susceptibilities of Mycoplasma Hominis, M. Pneumoniae, and Ureaplasma Urealyticum to GAR-936, Dalfopristin, Dirithromycin, Evernimicin, Gatifloxacin, Linezolid, Moxifloxacin, Quinupristin-dalfopristin, and Telithromycin Compared to Their...

Overview
Specialty Pharmacology
Date 2001 Aug 15
PMID 11502536
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

The susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to eight new antimicrobial agents were determined by agar dilution. M. pneumoniae was susceptible to the new glycylcycline GAR-936 at 0.12 microg/ml and evernimicin at 4 microg/ml, but it was resistant to linezolid. It was most susceptible to dirithromycin, quinupristin-dalfopristin, telithromycin, reference macrolides, and josamycin. M. hominis was susceptible to linezolid, evernimicin, and GAR-936. It was resistant to macrolides and the ketolide telithromycin but susceptible to quinupristin-dalfopristin and josamycin. U. urealyticum was susceptible to evernimicin (8 to 16 microg/ml) and resistant to linezolid. It was less susceptible to GAR-936 (4.0 microg/ml) than to tetracycline (0.5 microg/ml). Telithromycin and quinupristin-dalfopristin were the most active agents against ureaplasmas (0.06 microg/ml). The new quinolone gatifloxacin was active against M. pneumoniae and M. hominis at 0.12 to 0.25 microg/ml and active against ureaplasmas at 1.0 microg/ml. The MICs of macrolides were markedly affected by pH, with an 8- to 32-fold increase in the susceptibility of M. pneumoniae as the pH increased from 6.9 to 7.8. A similar increase in susceptibility with increasing pH was also observed with ureaplasmas. Tetracyclines showed a fourfold increase of activity as the pH decreased 1 U, whereas GAR-936 showed a fourfold decrease in activity with a decrease in pH.

Citing Articles

necrotising pneumonia in an immunocompetent adult male.

Pachunka J, Hankins R BMJ Case Rep. 2023; 16(6).

PMID: 37339824 PMC: 10314457. DOI: 10.1136/bcr-2022-250107.


Case Report: Double trouble: a rare case of successfully treated and co-infection.

Huang S, Tang Y, Wang J, Wang X, Zhang Y, Pan S Front Cell Infect Microbiol. 2023; 13:1159891.

PMID: 37197207 PMC: 10183579. DOI: 10.3389/fcimb.2023.1159891.


Prevalence and antibiotics resistance of species and in Hangzhou, China, from 2013 to 2019.

Song J, Wu X, Kong Y, Jin H, Yang T, Xie X Front Microbiol. 2022; 13:982429.

PMID: 36187990 PMC: 9520197. DOI: 10.3389/fmicb.2022.982429.


Integrating the Human and Animal Sides of Mycoplasmas Resistance to Antimicrobials.

Pereyre S, Tardy F Antibiotics (Basel). 2021; 10(10).

PMID: 34680797 PMC: 8532757. DOI: 10.3390/antibiotics10101216.


SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases.

Ferreira G, Santander A, Savio F, Guirado M, Sobrevia L, Nicolson G Biochim Biophys Acta Mol Basis Dis. 2021; 1867(12):166264.

PMID: 34481867 PMC: 8413106. DOI: 10.1016/j.bbadis.2021.166264.


References
1.
Yamaguchi T, Hirakata Y, Izumikawa K, Miyazaki Y, Maesaki S, Tomono K . In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan. Antimicrob Agents Chemother. 2000; 44(5):1381-2. PMC: 89878. DOI: 10.1128/AAC.44.5.1381-1382.2000. View

2.
Bebear C, Renaudin J, Charron A, Renaudin H, De Barbeyrac B, Schaeverbeke T . Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis. Antimicrob Agents Chemother. 1999; 43(4):954-6. PMC: 89234. DOI: 10.1128/AAC.43.4.954. View

3.
Bebear C, Renaudin H, Bryskier A, Bebear C . Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas. Antimicrob Agents Chemother. 2000; 44(7):1980-2. PMC: 89997. DOI: 10.1128/AAC.44.7.1980-1982.2000. View

4.
JAO R . Susceptibility of Mycoplasma pneumoniae to 21 antibiotics in vitro. Am J Med Sci. 1967; 253(6):639-50. DOI: 10.1097/00000441-196706000-00001. View

5.
Sabath L, LORIAN V, Gerstein D, LODER P, FINLAND M . Enhancing effect on alkalinization of the medium on the activity of erythromycin against gram-negative bacteria. Appl Microbiol. 1968; 16(9):1288-92. PMC: 547643. DOI: 10.1128/am.16.9.1288-1292.1968. View